150 related articles for article (PubMed ID: 12495381)
1. From the World Health Organization. Essential medicines: 25 years of better health.
JAMA; 2002 Dec; 288(24):3102. PubMed ID: 12495381
[No Abstract] [Full Text] [Related]
2. Privatized Pharmaceutical Innovation vs Access to Essential Medicines: A Global Framework for Equitable Sharing of Benefits.
Burci GL; Gostin LO
JAMA; 2017 Feb; 317(5):473-474. PubMed ID: 28170485
[No Abstract] [Full Text] [Related]
3. The concept of essential medicines: lessons for rich countries.
Hogerzeil HV
BMJ; 2004 Nov; 329(7475):1169-72. PubMed ID: 15539676
[TBL] [Abstract][Full Text] [Related]
4. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.
't Hoen E
Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298
[No Abstract] [Full Text] [Related]
5. [Research to support pharmaceutical policies].
Wirtz VJ; Reich MR; Hernández-Avila M
Salud Publica Mex; 2008; 50 Suppl 4():S427-8. PubMed ID: 19082252
[No Abstract] [Full Text] [Related]
6. MeTA: a welcome force for access to medicines.
Lancet; 2008 May; 371(9626):1724. PubMed ID: 18502276
[No Abstract] [Full Text] [Related]
7. Medicines in developing countries: a global health concern.
American Public Health Association
Am J Public Health; 1991 Feb; 81(2):256-60. PubMed ID: 11642868
[No Abstract] [Full Text] [Related]
8. TRIPS, pharmaceuticals, developing countries, and the Doha "solution".
Sykes AO
Chic J Int Law; 2002; 3(1):47-68. PubMed ID: 15709299
[No Abstract] [Full Text] [Related]
9. U.S., Switzerland oppose developing-country proposal on access to medicines.
James JS
AIDS Treat News; 2001 Sep; (371):5. PubMed ID: 11668978
[No Abstract] [Full Text] [Related]
10. Trade, TRIPS, and pharmaceuticals.
Smith RD; Correa C; Oh C
Lancet; 2009 Feb; 373(9664):684-91. PubMed ID: 19167054
[TBL] [Abstract][Full Text] [Related]
11. US changes trade policy on essential medicines.
Yamey G
BMJ; 1999 Dec; 319(7224):1521. PubMed ID: 10591704
[No Abstract] [Full Text] [Related]
12. WHO's essential drugs concept.
Lancet; 1990 Apr; 335(8696):1003-4. PubMed ID: 1970066
[No Abstract] [Full Text] [Related]
13. The courage to change the rules: a proposal for an essential health R&D treaty.
Dentico N; Ford N
PLoS Med; 2005 Feb; 2(2):e14. PubMed ID: 15736991
[TBL] [Abstract][Full Text] [Related]
14. Essential medicines in the Third World.
D'Arcy PF
Br Med J (Clin Res Ed); 1984 Oct; 289(6450):982-4. PubMed ID: 6435751
[No Abstract] [Full Text] [Related]
15. Availability and affordability of priority life-saving medicines for under-five children in health facilities of Tigray region, northern Ethiopia.
Abrha S; Tadesse E; Atey TM; Molla F; Melkam W; Masresha B; Gashaw S; Wondimu A
BMC Pregnancy Childbirth; 2018 Nov; 18(1):464. PubMed ID: 30497441
[TBL] [Abstract][Full Text] [Related]
16. Access to essential drugs.
Dev World Bioeth; 2001 Nov; 1(2):89-92. PubMed ID: 12870517
[No Abstract] [Full Text] [Related]
17. The morally uncomfortable global drug gap.
Cohen-Kohler JC
Clin Pharmacol Ther; 2007 Nov; 82(5):610-4. PubMed ID: 17898710
[TBL] [Abstract][Full Text] [Related]
18. Pharmaceuticals and the developing world.
Kremer M
J Econ Perspect; 2002; 16(4):67-90. PubMed ID: 15179979
[No Abstract] [Full Text] [Related]
19. The economics of essential drug programmes.
Smith GT
Soc Sci Med; 1987; 25(6):621-4. PubMed ID: 3686096
[TBL] [Abstract][Full Text] [Related]
20. No deal in sight on cheap drugs for poor countries.
Fleck F
BMJ; 2003 Mar; 326(7387):465. PubMed ID: 12609924
[No Abstract] [Full Text] [Related]
[Next] [New Search]
